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Abstract
Background: There is a growing body of evidence indicating that pediatric survivors of cancer are at a greater risk
of developing metabolic syndrome. This study evaluated some probable predictors of metabolic syndrome (MS),
such as leptin and adiponectin concentrations, the leptin/adiponectin ratio, insulin resistance, and adiposity, in a
sample of child survivors of lymphoma and leukemia in Mexico City.
Methods: Fifty two children (leukemia n = 26, lymphoma n = 26), who were within the first 5 years after cessation of
therapy, were considered as eligible to participate in the study. Testing included fasting insulin, glucose, adipokines and
lipids; body fat mass was measured by DXA. The MS components were analyzed according to tertiles of adipokines,
insulin resistance, and adiposity. Comparisons between continuous variables were performed according to the data
distribution. The MS components were analyzed according to tertiles of adipokines, insulin resistance, and adiposity.
With the purpose of assessing the risk of a present MS diagnosis, odds ratios (OR) with a 95% confidence interval (95%
IC) were obtained using logistic regression analysis according to the various metabolic markers.
Results: The median children age was 12.1 years, and the interval time from the completion of therapy to study
enrollment was 4 years. Among the MS components, the prevalence of HDL-C low was most common (42%), followed
by central obesity (29%). The HOMA-IR (OR 9.0, 95% CI 2.0; 41.1), body fat (OR 5.5, 95% CI 1.6; 19.3), leptin level (OR 5.7,
95% CI 1.6; 20.2) and leptin/adiponectin ratio (OR 9.4, 95% CI 2.0; 49.8) in the highest tertile, were predictive factors of
developing MS; whereas the lowest tertile of adiponectin was associated with a protective effect but not significant.
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Conclusions: Biomarkers such as HOMA-IR, leptin and leptin/adiponectin are associated with each of the components
of the MS and with a heightened risk of suffering MS among children survivors of cancer. Given the close relationship
between MS with risk of developing type 2 diabetes and cardiovascular disease, it is imperative to implement
prevention measures in this population and especially in developing countries where these pathologies have become
the leading cause of death.
Keywords: Childhood cancer survivors, Acute lymphoblastic leukemia and lymphoma, Metabolic syndrome,
Adipokines, Insulin resistance, Obesity
Background
The increase in the survival rates of child cancer patients
is accompanied by an increase in the likelihood to develop
long-term adverse effects. Specifically, survivors of ALL
(Acute lymphoblastic leukemia) and lymphoma are at risk
of developing metabolic abnormalities, such as obesity,
impaired glucose tolerance, insulin resistance, metabolic
syndrome, cardiovascular disease, and diabetes [1–4].
On the other hand, the excess adipose tissue that ac-
companies obesity alters the release of adipokines, in-
cluding leptin and adiponectin, which are known to
affect insulin sensitivity and vascular functionality,
thereby, increasing the risk of MS [5]. In fact, low adipo-
nectin and high leptin concentrations are observed in
children with MS and insulin resistance [5, 6]. This im-
balance between pro and anti-inflammatory adipokines
elicits low degree systemic inflammation, mainly associ-
ated with insulin resistance [7, 8]. Even more, both,
hypoadiponectinemia and hyperleptinemia are consid-
ered to be independent risk factors of the development
of type 2 diabetes and cardiovascular diseases [5, 7, 9–
13]. Owing to this fact, its plasmatic concentrations has
been proposed as a candidate biomarkers to identify
metabolic alterations including those of MS [14]. How-
ever, among children survivors of cancer it is not exactly
known how and to what extent IR, adiponectin and lep-
tin are associated with each of the components of MS.
Therefore the aim of this study was to evaluate some
probable predictors of MS, such as leptin and adiponec-
tin concentrations, the leptin/adiponectin ratio, insulin
resistance, and adiposity, in a sample of child survivorsof
ALL and lymphoma. To exclude random effects, these
factors were re-analyzed after 6 months.
Methods
Subjects
Children referred to the Pediatric Hospital from the
Mexican Institute of Social Security (IMSS) in Mexico
City who previously diagnosed with ALL or lymphoma,
and who were within the first 5 years after cessation of
therapy, without relapse, no second neoplasm or bone
marrow transplants were considered as eligible to par-
ticipate in the study.
From 61 potential candidates, 52 children met the se-
lection criteria (39 boys and 13 girls); Children who ac-
cepted to participate were asked to attend the pediatric
hospital on two occasions (baseline examination and 6
months later). This study was approved by the Research
and Ethics Committee of the Pediatric Hospital at the
Mexican Social Security Institute (2005/3603/071). We
obtained written informed consent from parents and in-
formed assent from children.
Procedures
Anthropometry
Body weight was measured with an electronic scale
(TANITA BWB-700, Tanita Corporation., Tokyo, Japan)
with the subjects wearing light-weight clothing. Height
was measured to the nearest 0.1 cm with a wall-
mounted stadiometer (SECA 222, SECA Corp., Oakland
Center, Columbia, MD, USA). Waist circumference was
measured at the level of the superior iliac crest to the
nearest 0.1 cm, and the values were changed to percen-
tiles according to Fernandez [15]. Body mass index
(BMI) and BMI percentiles for age and sex were calcu-
lated according to the Center of Disease Control (CDC)
normative curves using the computer software Epi-Info
(Obesity was defined conventionally as ≥95th percentile,
overweight as 85th to 94th percentile, and underweight as
<5th percentile [16]. Pubertal stage was determined on
the basis of the children’s self-assessment by using Tan-
ner’s standard photographs for pubic hair and genital de-
velopment. We did not measure testicular size in the
children [17].
Body composition
Body fat percentage (BFP) was determined by dual-
energy X-ray absorptiometry (DXA) using a GE Lunar
Prodigy Advance scanner (software version 9.0; GE
Medical Systems, Madison, WI, USA). The machine was
operated by only one technician.
Metabolic syndrome definition (MS)
Metabolic syndrome was defined in accordance with the
guidelines of the International Diabetes Federation (IDF)
[18], with the exception of the cutoff point for blood
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pressure, which was obtained from the National High
Blood Pressure Education Program Working Group on
high blood pressure in children and adolescents [19].
The rationale is that the cutoff point for blood pressure
used by the IDF does not properly represent the effects
of age, sex, and stature of children and adolescents. If
the IDF criterion is used for blood pressure, the preva-
lence of high blood pressure would be underestimated
because very few children exceed these values. There-
fore, children with metabolic syndrome were those with
Table 1 Metabolic characteristics of child survivors of acute lymphoblastic leukemia and lymphoma according to MS
Variables Firts Assessesment After 6 months
All No MS MS No MS MS
n 52 45 7 42 10
Sex (M) n (%) 39 75 33 73 6 86 31 74 8 80
Current age (Y)a 12.1 (7.1, 17.0) 12.2 (7.1, 17.0) 11.1 (7.1, 17.1) 12.1 (7.1, 17.0) 11.6 (7.1, 17.1)
Age at cancer diagnosis (Y)a 5.3 (1.0, 13) 6 (0.8, 13.0) 4 (2, 11.1) 6.1 (2.1, 13.0) 4.1 (0.08, 12.1)
Time since completion of therapy (Y)a 4 (2, 5) 4 (2, 5) 4 (2, 5) 4 (2, 5) 4 (2, 5)
Diagnosis (n %)
ALL 26 50 22 48.9 4 57.1 20 47.6 6 60.0
Lymphoma 26 50 23 51.1 3 42.9 22 52.4 4 40.0
Pubertal stage (n %)
1 33 63.5 28 62.2 5 71.4 18 42.9 7 70.0
≥ 2 19 36.5 17 37.8 2 28.6 24 57.1 3 30.0
Treatment recived (n %) 0.0
Ch 35 67.3 31 68.9 4 57.1 28 66.7 7 70.0
Ch + R 17 32.7 14 31.1 3 42.9 14 33.3 3 30.0
Nutritional Status (n %)
Normal 29 55.8 28 62.2 1 14.3 27 64.3 0 0
Overweight/Obesity 20 38.4 14 31.1 6 85.7 13 31.0 10 100
Low weight 3 5.8 3 6.7 0 0 2 4.8 0 0
MS Components median (min, max)
WC (cm) 70.5 (51.1, 105.7) 69.9 (51.1, 94.8) 78.1 (60.4, 105.7)* 50 (10, 100) 90 (90, 100)*
SBP (pc) 47 (2, 99) 42.5 (2, 93) 58 (14, 99) 16 (1, 70) 65 (19, 95)*
DBP (pc) 76 (15, 99) 75 (15, 97) 94 (19, 99)* 54 (11, 92) 94 (66, 99)*
Triglicerydes (mg/dL) 96.6 (34, 231) 85 (34, 205) 182 (117, 231)* 80 (28, 259) 169 (104, 264)*
HDL-C (mg/dL) 40 (18, 84) 40 (18, 84) 40 (18,46) 45 (20, 80) 37 (22, 68)
Glucose (mg/dL) 89 (74, 116) 89 (74, 116) 93 (76, 112) 93 (77, 105) 90 (83, 115)
Others metabolic variables median (min, max)
Insulin (μU/mL) 18.9 (4.3, 55) 18.7 (4.3, 55) 28.2 (17.5, 50)* 22.8 (3.4, 56.6) 31.5 (24.5, 64)*
HOMA-IR 4.3 (0.79, 13.9) 4.2 (0.79, 12.7) 7.4 (3.3, 13.9)* 5.2 (0.68, 13.8) 7.3 (5.2, 15.4)*
Adiponectin (μg/mL) 20.3 (1.3, 70) 23.4 (1.3, 70) 17.5 (11.7, 25.4) 20.2 (0.64, 57.3) 20.3 (8.3, 37.2)
Adiponectin per Kg fat (μg/mL/kg) 1.4 (0.07, 8.0) 1.6 (0.07, 8.0) 1.0 (0.38, 3.9)* 1.7 (0.06, 14.3) 0.90 (0.27, 3.8)
Leptin (ng/mL) 10.1 (1.2, 30.9) 8.0 (1.2, 30.9) 17.5 (8.5, 28.6)* 6.5, (1.1, 30.9) 22 (9.4, 28.2)*
Leptin (μg/mL/kg) 0.69 (0.11, 3.9) 0.69 (0.11, 3.9) 1.0 (0.35, 3.7) 0.65 (0.11, 4.8) 1.0 (0.30, 4.2)
Leptin to Adiponectin ratio 0.44 (0.06, 11) 0.35 (0.06, 11) 0.98 (0.69, 1.5)* 0.34 (0.05, 10.4) 1.1 (0.31, 1.7)*
Body Fat (%) 29.9 (8.3, 46.7) 27.6 (8.3, 44.4) 38.3 (31.2, 46.7)* 25.5 (7.2, 45.5) 39.8 (29.6, 49.3)*
VCAM (ng/mL) 925 (425, 1730) 930 (425, 1730) 769 (490, 1697) 753 (377, 2045) 683.9 (514, 1081)
ICAM (ng/mL) 459 (254, 1079) 468 (254, 1079) 412 (325, 685) 456.5 (184, 137) 404 (199, 631)
aValues are median (min, max); Abbreviations: MS Metabolic syndrome, Ch chemotherapy, Ch + R chemotheraphy + radiotherapy, HOMA-IR Homeostatic Model
Assessment of Insulin Resistance, VCAM Vascular cell adhesion molecule, ICAM Intercellular adhesion molecule; Comparations were assessed using Mann–Whitney
U-test due non-normal distribution of the data, and categorized data were analyzed using Fisher’s Test; * p value < 0.05
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central obesity based on a waist circumference (WC)
within ≥90th percentile adjusted for age, sex, and
Hispanic ethnicity and the presence of two or more of
the following features: a) hypertension as diastolic or
systolic blood pressure within ≥90th percentile for age
and sex; b) elevated triglyceride levels of ≥150 mg/dL; c)
low high-density lipoprotein cholesterol (HDL-c) level of
<40 mg/dL; and d) fasting glucose level of ≥100 mg/L.
Analytical methods
Venous blood samples were collected between 8:00 and
9:00 AM after a 12-h overnight fast. Serum aliquots were
separated and frozen at −80 °C until biochemical determin-
ation. Fasting glucose concentrations were determined by
the glucose oxidase method (Beckman Coulter Glucose
Analyzer; Beckman Coulter, Brea, CA, USA). Triglycerides,
total cholesterol, and HDL-C were measured by the enzym-
atic colorimetric method (SPIN 120 automatic analyzer
Shenzhen, Mindray) with commercially available kits. Lep-
tin and adiponectin levels, vascular cell adhesion molecule
(vCAM) and intercellular cell adhesion molecule (iCAM)
were determined in duplicate by ELISA (Human Adiponec-
tin, Leptin, vCAM and iCAM ELISA Kits, Millipore, St.
Charles, MO, USA), and insulin levels were determined by
radioimmunoassay using a commercial kit (Linco Research,
St. Charles, MO, USA). Insulin resistance (IR) was deter-
mined based on the fasting insulin and glucose concentra-
tions using the Homeostatic Model Assessment of Insulin
Resistance [HOMA-IR = (fasting insulin (μU/ml) * fasting
glucose (mmol/L)/22.5) [20]. Insulin resistance was defined
according to the percentile distribution by age and sex pro-
posed for Mexican children and adolescents [21].
Statistical analysis
All statistical analyses were performed using SPSS v.18.0
(SPSS Inc., Chicago, IL, USA) and STATA/SE v.11.0
(STATA Corp., College Station, TX, USA). The fre-
quency of MS and each component of MS were ob-
tained, and differences in proportions were assessed by
Fisher’s exact test. The data were grouped according to
the following characteristics: with or without MS fea-
tures, with or without MS diagnoses, by different cancer
treatments, as well as the nutritional status. Anthropo-
metric, metabolic, and inflammatory markers data were
tested for normal distribution based in skewness and
kurtosis and Shapiro-Wilk test; however, as log trans-
formation did not achieve normal distribution of some
of the studied variables such as adiponectin, we show
the medians instead of the log transformations of the
non-normally distributes variables. Comparisons be-
tween continuous variables were performed with Stu-
dent’s t test or the Mann–Whitney U test according to
data distribution. The MS components were analyzed
according to tertiles of adipokines, insulin resistance,
and adiposity. Differences in metabolic features between
the aforementioned tertile categories were obtained
using robust linear regression analysis. With the purpose
of assessing the risk of a present MS diagnosis, odds ra-
tios (OR) with a 95% confidence interval (95% IC) were
obtained using logistic regression analysis according to
the various metabolic marker tertiles; these data were
adjusted by sex, age, treatment, and diagnosis (lymph-
oma or ALL). The associations were re-evaluated at a 6-
month follow-up to validate that the findings observed
were not due to chance. Additionally, an analysis
between the metabolic variables with the changes ob-
served between baseline and 6-month measurements
was performed to identify which variables were most in-
fluenced by long-term changes. The changes between
first evaluation and 6-month measurements were ana-
lyzed in tertiles using the middle tertile as a reference
value because it was assumed that this tertile did not
show changes between the baseline and 6-month meas-
urement. Differences were considered significant at p <
0.05 with all P values based on two-sided tests.
Results
Demographic and clinical characteristics of participant
children are shown in Table 1. At entrance to the study,
the median age was 12.1 years, and the interval time
from the completion of cancer therapy to study enroll-
ment was 4 years. At enrollment, 38.4% of children were
classified as overweight or obese; after 6 months, the in-
cidence of overweight and obesity increased to 44%. In
the same table, the child survivors of leukemia and
lymphoma were classified according the presence of MS
Table 2 Prevalence and components of metabolic syndrome in
child survivors of acute lymphoblastic leukemia and lymphoma
MS First assessment After 6 months
n 52 52
WCa ≥90 pcb 15 (28.8) 15 (28.8)
Triglycerides ≥150 mg/dL 9 (17.3) 12 (23.1)
HDL-Cc <40 mg/dL 22 (42.3) 22 (42.3)
High BPd 14 (26.9) 8 (15.4)
Glucose >100 mg/dL 4 (7.7) 9 (17.3)
No. of MS criteria
0 14 (26.9) 17 (32.7)
1 criteria 19 (36.5) 17 (32.7)
2 criteria 12 (23.1) 8 (15.4)
3 criteria 6 (11.5) 6 (11.5)
4 criteria 1 (1.9) 4 (7.7)
MS 7 (13.5) 10 (19.2)
Values are Number (percentage); Abbreviations: MS Metabolic syndrome, aWC
Waist circumference, pcb Percentile, cHDL-C High density lipoprotein
cholesterol, dSystolic blood pressure ≥90 pc or Diastolic blood pressure ≥90 pc
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diagnosis at first and 6 months assessments, and as ex-
pected, the insulin levels, HOMA-IR index, leptin levels
(ng/mL), leptin/adiponectin ratio, and BFP, differed sig-
nificantly between children with and without MS.
Among the MS components, the prevalence of HDL-C
low was most common (42.3%), followed by central
obesity (28.8%). At 6 months, the number of patients
with a diagnosis of MS increased to 19%. Additionally,
increasing trends in the number of children with alter-
ations in triglycerides (17.3 to 23.1%), and glucose levels
(7.7 to 17.3%) and in the number who presented with 4
criteria for the diagnosis of MS (2 to 7.7%) were ob-
served (Table 2).
The metabolic characteristics of the child survivors of
leukemia and lymphoma according to the treatment re-
ceived and nutritional status are presented in Tables 3 and
4. The results of the analysis of metabolic markers in all
the children who received chemotherapy and those who
received radiotherapy besides chemotherapy did not sig-
nificantly differ. Of all the children, 35 (67%) received
Table 3 Metabolic characteristics of child survivors of leukemia and lymphoma according to treatment received at first assessment
Treatment
Chemotherapy n = 32a Chemotherapy plus radiotherapy n = 17b
Variables Normal Overweigth/Obese Normal Overweigth/Obese
n: number (%) 17 15 (47) 12 5 (29)
Sex (M) 12 12 9 4
Current age (Y) 12.1 (8.1, 17.0) 12 (7.1, 17.0) 12.6 (7.1, 16.1) 12.1 (8.0, 17.1)
Age at cancer diagnosis (Y) 6.0 (2.0, 13.0) 4.0 (2.0, 12.1) 6.5 (0.08, 12.1) 7 (1.0, 11.1)
Time since completion of therapy (Y) 4.0 (2.0, 5.1) 4.0 (2.1, 5.1) 3.1 (3.0, 5.0) 4.0 (2.0, 5.0)
Weight (kg) 46.9 (18.1, 91.2) 48.9 (26.2, 102.9)
Height (cm) 148.4 (116.2, 178) 157.9 (123, 176.1)
Diagnosis : ALL/Lymphoma 11/6 9/6 4/8 1/4
Pubertal stage
1 9 13* 5 3
≥ 2 8 2 7 2
MS Components
WC (pc) 25 (10, 75) 90 (50, 100)* 50 (10, 90) 90 (75, 100)
SBP (pc) 47 (3, 92) 53 (18, 93) 17 (2, 65) 47 (20, 99)
DBP (pc) 76 (15, 94) 82 (57, 99) 75 (19, 96) 89 (39, 99)
Triglicerydes (mg/dL) 76 (34, 149) 114 (50, 231) 72 (35, 164) 188 (148, 210)
HDL-C (mg/dL) 42 (25, 84) 39.5 (26, 78) 42 (18, 64) 43 (18, 48)
Glucose (mg/dL) 90 (75.5, 115.7) 91 (76, 105.7) 86 (74, 112.5) 93 (82, 99)
Others metabolic variables
Insulin (μU/mL) 16.3 (9.1, 38.7) 24.9 (14.2, 35.3)* 20.5 (4.3, 50) 36.3 (19, 55)
HOMA-IR 3.6 (1.7, 9.5) 5.5 (2.8, 8.2)* 4.3 (0.79, 13.9) 8.3 (4.7, 12.7)
Adiponectin (μg/mL) 23 (1.3, 44.3) 22 (6.8, 70) 19.1 (11.7, 41.2) 16 (1.3, 27.6)
Adiponectin per Kg fat (μg/mL/kg) 1.5 (0.39, 6.7) 1.2 (0.28, 4.9) 1.8 (0.51, 5.1) 0.75 (0.7, 1.8)
Leptin ((μg/mL) 4.4 (2, 13.4) 18.2 (9.8, 30.9)* 7.4 (1.2, 19.0) 17.5 (13.5, 18.5)
Leptin per Kg fat (μg/mL/kg) 0.49 (0.11, 3.0) 1.0 (0.34, 3.7)* 0.46 (0.16, 3.9) 0.72 (0.53, 1.31)
Leptin to Adiponectin ratio 0.27 (0.08, 2.7) 0.98 (0.20, 3.0)* 0.33 (0.06, 0.76) 0.85 (0.67, 11.0)
Body Fat (%) 23.4, (9.9, 36.2) 38.3 (32.0, 46.7)* 27.4 (8.3, 38.1) 37.1 (28.5, 40.2)
VCAM (ng/mL) 1058 (561, 1727) 818 (425, 1730) 856 (586, 1207) 989 (490, 1697)
ICAM (ng/mL) 459 (254, 661) 418 (294, 1079) 500 (265, 952) 398 (324, 598)
MS
Yes/No 0/17 4/11 1/11 2/3
Values are median (min, max); Abbreviations: MS Metabolic syndrome, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, VCAM Vascular cell adhesion
molecule, ICAM Intercellular adhesion molecule. aThree children of Chemotherapy group were excluded, because they were underweight; Data compared Mann–Whitney
U-test and categorized data were analyzed using Fisher’s Test, *p value < 0.05; bIt was not possible to compare statistically (sample size)
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chemotherapy only, of whom 15 (47%) were classified as
overweight or obese. All of the metabolic syndrome com-
ponents were similar in the chemotherapy group (normal
group vs overweight/obese group), except for waist cir-
cumference (p < 0.0001) and other metabolic variables
such as insulin level (16.3 μU/mL vs 24.9 μU/mL, p =
0.010), HOMA-IR index (3.6 vs 5.5, p = 0.033), leptin level
(4.4 ng/mL vs 18.2 ng/mL, p < 0.0001), leptin-to-
adiponectin ratio (0.27 vs 0.98, p < 0.0001), and fat mass
percentage (23.4 vs 38.3, p < 0.001). However, the group of
children who received chemotherapy plus radiotherapy
could not be statistically compared because only five
(29%) of the 17 children were classified into the over-
weight/obese subgroup. However, the overweight/obese
children tended to exhibit higher values than the healthy
children did, in terms of insulin levels (20.5 μU/mL vs
36.3 μU/mL), HOMA-IR index (4.3 vs 8.3), and leptin
level (7.4 pg/mL vs 17.5 pg/mL) (Table 3). The analysis of
changes in weight and height between the baseline meas-
urement and 6 months after treatment according to the
Table 4 Metabolic characteristics of child survivors of leukemia and lymphoma according to treatment at 6-months
Treatment
Chemotherapya n = 32 Chemotherapy plus radiotherapy n =17
Variables Normal Overweigth/Obese Normal Overweigth/Obese
n: number (%) 18 14 (40) 9 8 (47)
Sex: M 13 11 6 7
Current age (Y) 12.5 (8.0, 17.1) 11.6 (8.0, 17.1) 14.0 (8.4, 17.0) 13.0 (8.1, 18.0)
Age at cancer diagnosis (Y) 6.0 (2, 13) 4.0 (2, 12) 6.0 (0.08, 12) 70 (1.0, 11.1)
Time since completion of therapy (Y) 4.0 (2.1, 5.0) 4.0 (2.1, 5.0) 3.1 (3.0, 5.0) 4.0 (2.0, 5.0)
Δ Body weight (kg) (6 mo - first assessement) 1.6 (−2.5, 5.3) 2.0 (−1.2, 5.1)
Δ Height (cm) (6 mo - first assessment) 2.6 (1.7, 6.0) 1.0 (0.2, 3.5)*
Diagnosis : ALL/Lymphoma 11/7 9/5 3/6 2/6
Pubertal stage
1 8 9 3 2
≥ 2 10 5 6 6
MS Components
WC (pc) 25 (10, 50) 90 (35, 100)* 30 (10, 50) 83 (50, 90)**
SBP (pc) 15.5 (0, 55) 64 (2, 95)* 13 (1, 38) 21 (3, 65)
DBP (pc) 54 (22, 92) 87 (13, 99)* 53 (38, 79) 71 (39, 85)
Triglicerydes (mg/dL) 80 (28, 191) 124 (66, 264)* 91 (28, 259) 105 (56, 218)
HDL-C (mg/dL) 47.3 (24.6, 79.5) 38.5 (21.7, 67.6)* 46 (32, 56) 37 (20, 60)
Glucose (mg/dL) 93 (76.6, 102) 97.5 (83.5, 115) 88.5 (76.6, 100.6) 92.6 (82.7, 101.2)
Others metabolic variables
Insulin (μU/mL) 25 (8.3, 35.4) 33.4 (22.8, 64)* 14.9 (3.4, 43.9) 28.9 (16.9, 52.3)
HOMA-IR 4.8 (1.7, 7.0) 7.8 (5.2, 15.4)* 3.4 (0.68, 10.9) 6.6 (4.0, 11.4)
Adiponectin (μg/mL) 21.9 (7.7, 42.1) 20.2 (6.6, 57.3) 20.9 (11.6, 28.9) 15.3 (0.64, 33.0)
Adiponectin per Kg fat (μg/mL/kg) 1.7 (0.45, 14.3) 1.0 (0.27, 4.2) 1.9 (0.62, 4.2) 0.78 (0.06, 6.6)
Leptin ((μg/mL) 5.2 (1.8, 30.9) 21 (9.4, 40.7)* 6.2 (1.6, 25.1) 9.5 (3.6, 27.6)
Leptin per Kg fat (μg/mL/kg) 0.63 (0.13, 2.6) 1.1 (0.30, 4.4)* 0.39 (0.11, 4.8) 0.67 (0.13, 4.2)
Leptin to Adiponectin ratio 0.26 (0.05, 1.1) 1.2 (0.81, 3.5)* 0.34 (0.11, 1.2) 0.93 (0.11, 10.4)
Body Fat (%) 22 (11.2, 35.7) 39.8 (33.4, 49.3)* 23 (10.9, 43.4) 30.7 (18.7, 37.7)
VCAM (ng/mL) 801 (503, 2045) 818 (514, 1522) 617 (377, 1166) 727 (394, 1178)
ICAM (ng/mL) 404 (234, 753) 440 (200. 1124) 571 (184, 966) 411 (307, 1037)
MS
Yes/No 0/18 7/14 0/9 3/5
Values are median (min, max); Abbreviations: MS Metabolic syndrome, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, VCAM Vascular cell adhesion
molecule, ICAM Intercellular adhesion molecule. Data compared Mann–Whitney U-test. Categorized Data were analyzed using Fisher’s Test. aThree children of
Chemotherapy group were excluded, because they were underweight; * p value < 0.05; **p value = 0.065
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type of therapy received revealed significant differences in
height. The height of the children in the chemotherapy
group increased by 2.6 cm (range: 1.7–6.0), while that of
the children in the radiotherapy plus chemotherapy group
showed a growth of 1.0 cm (range: 0.2–3.5; p = 0.035)
(Table 4). We wish to indicate that age did not signifi-
cantly differ between the treatment groups. At 6 months,
all of the metabolic syndrome components were similar in
the chemotherapy plus radiotherapy group (normal group
vs overweight/obese group).
In the Table 5 are shown the analysis of the MS com-
ponents and the aforementioned metabolic variables
compared with biomarkers expressed in tertiles indi-
cated that children who were classified in the highest
tertile for BFP, leptin, and leptin/adiponectin ratio had a
higher WC and higher levels of triglycerides, insulin,
and HOMA index. Children in the highest tertile of the
HOMA index had lower levels of adiponectin, and
higher waist circumference, triglycerides, and leptin
levels compared to children who were in the lowest ter-
tile of the HOMA index.
At 6 months, utilizing the tertile without changes as
a reference (Table 6), children who reduced their BFP
also reduced their WC and insulin concentration.
However, the children who increased HOMA index
values had a 2.5 cm greater WC, 5.1 mg/dL higher
glucose, and 30 mg/dL higher triglycerides. In con-
trast to these findings, when children reduced their
leptin concentrations, their glucose levels decreased.
On the contrary, when they reduced their adiponectin
values, their HDL-C levels also decreased. Similarly,
when the leptin/adiponectin ratio tertile decreased,
decreases in the levels of glucose, triglycerides, fasting
insulin and HOMA index were also observed.
Table 7 shows that the odds of developing MS at the
first assessment were higher in those with a BFP (OR
5.1, 95% CI 1.9 to 22.0), leptin level (OR 4.8, 95% CI 1.4
to 17.2) and leptin/adiponectin ratio (OR 5.2 95% CI 1.2
to 22.6) in the highest tertile, whereas the lowest tertile
of adiponectin was associated with a protective but not
significant effect. Similar findings were also observed
after 6 months. The HOMA index only was a predictive
factor of developing MS at 6 months.
Discussion
Our study showed that during early surveillance, the
adiposity, HOMA-IR index, concentration of leptin,
and leptin/adiponectin ratio are strongly associated
with MS development in children surviving lymphoma
and ALL. In contrast, the adiponectin concentration
seems to have a protective effect on the development
of this syndrome.
In our sample of child cancer survivors, the esti-
mated frequencies of MS tended to be greater than
those observed by Kourti (5.8%) [22], Trimis [23]
(11.2%), Chow [24] (10.8%) and Aldhafiri [25] (7.1,
5.4%) and similar to those reported by Reisi [26]
(20%). This variation in the frequency of MS is prin-
cipally due to the lack of consistent criteria and cut-
off points in its definition. However, our results are
similar to several studies conducted in Mexico in an
open pediatric population that used the same defin-
ition. For example, the Juarez et al. study [27], re-
ports a prevalence of 20% in children and obese
adolescents with ages from 11 to 13 years, whereas
Klunder et al. [14] reported a prevalence of 13% in
obese children 6–12 years.
In our Country, there are no statistics regarding the
number of survivors of childhood cancer reaching
adulthood. However, within the Hematology and On-
cology Services at our hospital, we observed a gradual
increase in this group of patients. Mexico is a country
with the highest prevalence of overweight and obesity
in the world. In this context, MS is considered to be a
complex clinical condition that is associated with early
obesity and other metabolic risk factors associated with
the start of its development during childhood. In vari-
ous studies, an increase in the frequency of obesity in
survivors of childhood cancer has been observed [3,
28]. We also found that the percentages of leukemia
and lymphoma survivors presented combined preva-
lence rates of overweight and obesity that were slightly
greater (38 and 42%) than those reported by the
National Health Survey (ENSANUT 2012) [29] in a
Mexican pediatric population (35%). This finding is
relevant given that central obesity can cause insulin re-
sistance, a metabolic alteration that is found in the ma-
jority of individuals with MS and which increases the
risk of type 2 diabetes and cardiovascular disease [30,
31]. In this study, approximately 80% of the surviving
youths presented high levels of insulin and resistance to
insulin. In these children, hyperinsulinemia compen-
sates for insulin resistance and maintains the homeo-
stasis of insulin. However, even without alterations in
the metabolism of glucose, the risk of presenting with
additional health problems exists, such as early athero-
sclerosis, hypertension, and so on.
Currently, given the increase in complications associ-
ated with MS, various molecules have been proposed to
predict the risk of this syndrome in both general popu-
lation and pediatric cancer survivor patients. The main
observations of this study were that childhood cancer
survivors in the highest tertile of the leptin/adiponectin
ratio, BFP, and HOMA index presented with lower
levels of adiponectin per/kg/fat, a greater waist circum-
ference, high concentrations of leptin and triglycerides,
a higher systolic blood pressure and lower HDL-C con-
centrations. In this study, BFP and the leptin-to-
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Coeficient −3.8 0.6 −0.1 2.5 −0.3 0.6 −0.1 2.7 −1.5 2.5
95% CI −6.2;-1.4 −1.7;2.8 −2.4; 2.3 0.1; 4.9 −2.9; 2.4 −2.2; 3.3 −2.6; 2.5 0.1; 5.3 −3.9; 0.9 0.1; 5.0
P 0.003 0.623 0.950 0.041 0.850 0.668 0.963 0.041 0.218 0.042
Blood Pressure (mmHg)
Systolic BP
Coeficient 0.1 −6.8 5.1 6.7 −3.5 −4.0 −3.5 −1.7 −7.3 −5.4
95% CI −9.2; 9.5 −15.5;1.9 −2.8; 13.1 −1.3; 14.6 −12.3; 5.3 −12.8; 4.8 −12.5; 5.6 −10.9; 7.5 −16.1; 1.6 −14.3; 3.6
P 0.975 0.123 0.202 0.098 0.425 0.361 0.447 0.709 0.104 0.235
Diastolic BP
Coeficient −5.6 −7.7 6.1 3.6 −2.9 2.2 −5.1 −0.2 −3.4 −3.5
95% CI −13.9; 2.6 −15.3;-0.0 −1.1; 13.3 −3.5; 10.8 −10.3; 4.5 −5.1; 9.6 −12.6; 2.4 −7.9; 7.4 −11.1; 4.2 −11.3; 4.2
P 0.175 0.049 0.093 0.312 0.433 0.542 0.180 0.955 0.375 0.366
Glucose
Coeficient 0.3 1.9 −5.5 5.1 −2.0 −1.7 −6.9 1.7 −5.9 1.5
95% CI −6.4; 6.9 −4.4; 8.1 −10.4; −0.7 0.2; 10.0 −7.9; 4.0 −7.8; 4.4 −12.3; -1.5 −3.7;7.2 −11.5; 0.4 −4.1; 7.2
P 0.936 0.549 0.027 0.043 0.509 0.568 0.013 0.529 0.037 0.590
Triglycerides
Coeficient −3.8 −5.4 −3.6 30.0 9.4 1.7 −8.9 2.9 −40.7 −10.8
95% CI −37.7; 30.2 −37.6; 26.8 −31.5; 24.3 1.7; 58.3 −22.2; 41.0 −30.5; 33.8 −41.1; 23.2 −29.8; 35.5 −70.4; −11.1 −40.9; 19.4
P 0.823 0.738 0.797 0.038 0.551 0.918 0.579 0.861 0.008 0.476
HDL-C
Coeficient 0.6 −1.8 2.4 3.6 −8.3 −0.5 1.0 3.0 2.6 0.3
95% CI −7.1; 8.4 −9.0; 5.4 −4.2; 9.0 −3.2; 10.4 −14.5; −2.1 −6.9; 5.9 −6.0; 8.0 −4.2; 10.2 −4.4; 9.6 −6.9; 7.6
P 0.867 0.620 0.469 0.288 0.010 0.886 0.770 0.401 0.453 0.926
Adipokines
Adiponectin
Coeficient 0.1 −3.9 5.8 2.5 - - −1.2 −2.4 - -
95% CI −4.0; 4.8 −9.0; 1.3 1.3; 10.3 −2.3; 7.3 −6.1; 3.8 −7.4; 2.6
P 0.980 0.138 0.013 0.298 0.639 0.332
Leptin
Coeficient 0.3 1.4 −1.8 1.1 2.8 3.5 - - - -
95% CI −4.3; 4.9 −2.9; 5.6 −5.5; 1.9 −2.8; 5.0 −0.8; 6.5 −0.2; 7.1
P 0.895 0.511 0.331 0.569 0.130 0.063
Insulin resistance
Fasting insulin (mμ/mL)
Coeficient −6.9 0.1 - - −1.1 −6.3 −4.1 2.5 −7.6 2.4
95% CI −12.7; -1.1 −5.8; 6.0 −7.8; 5.7 −13.2; 0.6 −11.1; 2.9 −4.6; 9.6 −14.1; −1.1 −4.3; 9.0
P 0.020 0.978 0.753 0.072 0.241 0.480 0.023 0.476
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adiponectin ratio were strong predictors of MS, with
odds ratios of 9 and 9.4, respectively. For this reason,
the measurement of these metabolic variables in early
surveillance screenings can be useful to identify individ-
uals who are susceptible to metabolic risk. In the lep-
tin/adiponectin relationship, this measurement can be
considered to be an indicator of sensitivity to insulin in
youth who have survived childhood cancer. However, it
should be noted that adiponectin, an adipocytokine
with antiatherogenic, antidiabetogenic, and anti-
inflammatory functions that is known as a predictor of
MS in children [7, 14, 32] did not show this association.
This observation can most likely be explained by the
high number of participants who presented with IR, as
previous studies revealed that individuals with IR
present lower serum levels of adiponectin, independent
of sex, age and ethnicity [33, 34]. Similarly, the change
in these indicators demonstrated a direct effect on the
metabolic profiles of children. In contrast, an increase
in the concentration of adiponectin at 6 months
showed a trend toward reduced concentrations of insu-
lin and HOMA index, without reaching statistical sig-
nificance. In child cancer survivors, few studies have
evaluated the role of these adipokines, in addition to
levels of insulin, adiposity and the presence of MS.
Tonorezos et al. [35], in a cross-sectional study of 116
adult survivors of childhood leukemia (median age,
23 years), reported that survivors presented high levels
of leptin associated with body fat and insulin resistance.
In a more recent study that is similar to ours, Kojima
et al. [36] reported that low levels of total adiponectin
were associated with a greater number of patients with
hypertriglyceridemia and hypertension.
Based on these results, we should discuss the strengths
and limitations of our work. Given the nature of the
study, survival bias could not be avoided, as only pa-
tients who were alive at the time of the study was con-
ducted could be evaluated. This bias is important
because in developing countries, such as Mexico, the
survival rate of children with ALL at 5 years is less than
that reported in developed countries (73 vs 90%) [37].
Therefore, our findings could not be extrapolated to de-
veloped countries. However, in developing countries
with survival rates similar to ours, the results could have
external validity. It was also difficult to determine
whether the percentage of obesity found in these chil-
dren is primarily related to the treatment received
(chemotherapy, radiation therapy or both), as the nutri-
tional state of the metabolic variables at the time of
diagnosis and during treatment is not known. However,
currently, various studies conducted in this population
have indicated an increase in the incidence of obesity
and resistance to insulin related to treatment in ALL
and lymphoma survivors during therapy [38]. The devel-
opment of these metabolic alterations has been related
to a deficiency in the secretion of growth hormone, not
only in those patients who received brain radiation but
also in those who have received chemotherapy or stem
cell transplants [6]. In this study, survivors of childhood
ALL and lymphoma are at increased risk of short stat-
ure, the risk is highest for those treated with radiother-
apy. Another possible explanation for the increased risk
of developing components of MS in this population is
related to corticosteroid therapy, as it is widely accepted
that children who receive steroids gain weight [6]. An
additional limitation was that pubertal stage was
Table 6 Analysis of metabolic variables with the components of metabolic syndrome at 6-months (Continued)
HOMA-IR
Coeficient 1.8 1.7 - - −0.4 −1.7 −1.1 0.9 −2.2 0.8
95% CI 0.1; 3.4 0.1; 3.4 −2.2; 1.5 −3.6; 0.2 −3.1; 0.8 −1.0; 2.9 −3.9; -0.4 −1.0; 2.6
P 0.033 0.043 0.708 0.083 0.237 0.345 0.017 0.387
Values obtained through robust linear regression analysis, adjusted for gender, age, treatment (only chemotherapy or chemotherapy plus radiotherapy), and and
diagnoses (acute lymphoblastic leukemia or lymphoma). Regression coefficients are change in outcome variable per tertile change in fat percentage, HOMA-IR Adi-
ponectin, leptin, and Leptin adiponectin ratio. The referent was stable tertile
Table 7 Odds ratio of developing metabolic syndrome according to different metabolic variables
Variable First assessment After 6 months
ORa 95% IC P ORa 95% IC p
Body fat percentage 5.1 1.9; 22.0 0.028 9.0 2.0; 41.1 0.004
HOMA-IR index 2.3 0.2; 1.4 0.137 5.5 1.6; 19.3 0.007
Leptin 4.8 1.4; 17.2 0.015 5.7 1.6; 20.2 0.007
Adiponectin 0.5 0.2; 1.5 0.189 0.9 0.4; 2.0 0.728
Leptin to adiponectin ratio 5.2 1.2; 22.6 0.027 9.4 2.0; 43.8 0.004
aOR obtained through logistic regression, by tertil change and adjusted for gender, age, treatment (only chemotherapy or chemotherapy plus radiotherapy), and
diagnoses (acute lymphoblastic leukemia or lymphoma)
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determined on the basis of the children’s self-assessment
using Tanner’s standard photographs for pubic hair and
genital development, which is a more subjective meas-
ure, as it depends on the patient’s self-assessment. Valid-
ation studies showed that self-assessment is inferior to
clinical assessment [39]. In addition, in this study, we
have not analyzed what kinds of food they were eating
and their physical activity. On the other hand, the pres-
ence of MS increases cardiovascular risk and vascular
brain disease as a consequence of premature changes in
the arterial wall, including endothelial cell damage [40].
In this sample of child cancer survivors, endothelial
function (in terms of VCAM and ICAM) was not differ-
ent between those who received only chemotherapy and
those who received radiation therapy and between those
who were diagnosed with MS and those who did not de-
velop MS. To validate that the findings were not due to
chance, a second measurement at 6 months was con-
ducted. This second measurement confirmed that most
of the findings observed in the first measurement were
stable at 6 months. Variables such as BFP were obtained
using the DXA technique, which is considered to be reli-
able and precise in children. With regard to the meta-
bolic and biochemical variables, standard techniques
were employed to quantify their concentration in a spe-
cialized research laboratory. It was determined that a
greater number of metabolic variables were reported
than in other studies.
Conclusions
Biomarkers such as HOMA-IR, leptin and leptin/adipo-
nectin are associated with each of the components of
the MS and with a heightened risk of suffering MS
among children survivors of cancer. Given the close re-
lationship between MS with risk of developing type 2
diabetes and cardiovascular diseases, it is imperative to
implement prevention measures in this population and
especially in developing countries where these patholo-
gies have become the leading cause of death.
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